bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $0.24 and traded as low as $0.2180. bioAffinity Technologies shares last traded at $0.1970, with a volume of 702 shares traded.
bioAffinity Technologies Stock Down 19.5%
The business’s 50-day moving average price is $0.30 and its 200-day moving average price is $0.24.
bioAffinity Technologies Company Profile
bioAffinity Technologies, Inc is a biotechnology company focused on developing noninvasive diagnostic tests and targeted cancer therapies. The company’s technology uses porphyrin compounds, which can bind to cancer cells and other biological targets, with the goal of improving the detection and treatment of cancer.
Its lead diagnostic product, CyPath Lung, is an investigational urine-based test designed to aid in the detection of lung cancer, including at earlier stages. The test uses a fluorescent porphyrin compound and flow cytometry to identify cancer-associated signals in urine.
Further Reading
- Five stocks we like better than bioAffinity Technologies
- LyondellBasell’s Dividend Looks Safer, But a New Risk Could Change That
- L3Harris Stock Took a Beating—Is a 20% Rebound Next?
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
